# Optimized Treatment and Regression of HBV-induced Liver Fibrosis

> **NCT01938781** · PHASE4 · COMPLETED · sponsor: **Beijing Friendship Hospital** · enrollment: 400 (actual)

## Conditions studied

- Liver Fibrosis

## Interventions

- **DRUG:** entecavir
- **DRUG:** Peg-IFN

## Key facts

- **NCT ID:** NCT01938781
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2018-07-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01938781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01938781, "Optimized Treatment and Regression of HBV-induced Liver Fibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01938781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*